Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging
…, N Boddaert, A Tauziède‐Espariat, S Picot… - Brain …, 2019 - Wiley Online Library
Ependymoma with RELA fusion has been defined as a novel entity of the revised World
Health Organization 2016 classification of tumors of the central nervous system (CNS), …
Health Organization 2016 classification of tumors of the central nervous system (CNS), …
Copy-number alterations reshape the classification of diffuse intrinsic pontine gliomas. First exome sequencing results of the BIOMEDE trial
…, A Moussa, S Ghermaoui, E Barret, S Picot… - medRxiv, 2021 - medrxiv.org
Diffuse intrinsic pontine gliomas (DIPG) is an incurable neoplasm occurring mainly in children
for which no progress was made in the last decades. The randomized phase II BIOMEDE …
for which no progress was made in the last decades. The randomized phase II BIOMEDE …
DIPG-20. Pre-randomisation central review and real-time biomarkers screening in the multicentre biological medicine for dipg eradication (biomede) trial: lessons …
…, E Lechapt-Zalcman, E Barret, S Picot… - Neuro …, 2018 - academic.oup.com
Diffuse intrinsic pontine gliomas (DIPG) with H3.1K27M mutation are associated with dismal
prognosis and median survival of 15.0 months. We present a patient with diffuse H3.1K27M …
prognosis and median survival of 15.0 months. We present a patient with diffuse H3.1K27M …
PDTM-36. WHOLE EXOME SEQUENCING (WES) OF DIPG PATIENTS FROM THE BIOMEDE TRIAL REVEALS NEW PROGNOSTIC SUBGROUPS WITH SPECIFIC …
…, C Chappé, S Ghermaoui, E Barret, S Picot… - Neuro …, 2019 - ncbi.nlm.nih.gov
BACKGROUND & METHODS. The BIOlogical MEdicines for DIPG Eradication (BIOMEDE)
trial is a randomized multi-arm multi-stage program (drop-the-loser adaptive design). The first …
trial is a randomized multi-arm multi-stage program (drop-the-loser adaptive design). The first …
DIPG-21. Genomic landscape of the first 100 tumors registered in the biological medicine for DIPG eradication (BIOMEDE) trial
D Castel, E Barret, S Picot, A Plessier, L Le Dret… - Neuro …, 2017 - ncbi.nlm.nih.gov
BACKGROUND: Genomic analyses of DIPG have been so far mostly performed on autopsy
samples or in retrospective studies. In the frame of the BIOMEDE randomized trial of three …
samples or in retrospective studies. In the frame of the BIOMEDE randomized trial of three …
Atypical symptoms, SARS-CoV-2 test results and immunisation rates in 456 residents from eight nursing homes facing a COVID-19 outbreak
…, M Albrand, S Miot, Y Rolland, MC Picot… - Age and …, 2021 - academic.oup.com
Background Frail older persons may have an atypical presentation of coronavirus disease
2019 (COVID-19). The value of real-time reverse-transcriptase polymerase chain reaction (rRT…
2019 (COVID-19). The value of real-time reverse-transcriptase polymerase chain reaction (rRT…
HGG-42. GLIOMA ONCOGENESIS IN CONSTITUTIONNAL MISMATCH REPAIR DEFICIENCY (CMMRD) SYNDROME: A CLINICO-PATHOLOGICAL AND …
…, MA Debily, L Guerrini-Rousseau, S Picot… - Neuro …, 2018 - ncbi.nlm.nih.gov
Glioma are frequently seen in the second decade of life in children with constitutional mismatch
repair deficiency (CMMRD) syndrome. They are often associated with a high mutation …
repair deficiency (CMMRD) syndrome. They are often associated with a high mutation …
Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: the CONsort‐19 study
…, L Gamon, A Pisoni, S Miot, Y Rolland, MC Picot… - Allergy, 2022 - Wiley Online Library
Background The humoral immune response following COVID‐19 vaccination in nursing home
residents is poorly known. A longitudinal study compared levels of IgG antibodies against …
residents is poorly known. A longitudinal study compared levels of IgG antibodies against …
Strong decay of SARS-CoV-2 spike antibodies after 2 BNT162b2 vaccine doses and high antibody response to a third dose in nursing home residents
…, E Tuaillon, L Gamon, A Pisoni, S Miot, MC Picot - Journal of the American …, 2022 - Elsevier
Objectives To measure the antibody decay after 2 BNT162b2 doses and the antibody response
after a third vaccine dose administered 6 months after the second one in nursing home …
after a third vaccine dose administered 6 months after the second one in nursing home …
Receptor binding domain‐IgG levels correlate with protection in residents facing SARS‐CoV‐2 B. 1.1. 7 outbreaks
…, S Rafasse, AM Dupuy, N Gros, D Muriaux, MC Picot… - Allergy, 2022 - Wiley Online Library
Background Limited information exists on nursing home (NH) residents regarding BNT162b2
vaccine efficacy in preventing SARS‐CoV‐2 and severe COVID‐19, and its association …
vaccine efficacy in preventing SARS‐CoV‐2 and severe COVID‐19, and its association …
